Literature DB >> 8172356

Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis.

T Löfkvist1, B Agrell, S Dreborg, G Svensson.   

Abstract

Immunotherapy (IT) was performed for 12 months with a purified and standardized preparation of Dermatophagoides farinae. Twenty adults with rhinoconjunctivitis sensitive to house-dust mite were given IT, and a similar group of 11 patients served as open controls. A total of 512 injections were given. Twenty-eight episodes of allergic side-effects occurred, 13 general and 15 local, most of them during the initial incremental dose period. No severe reactions started later than 30 min after the injection. One patient suffered anaphylactic shock. In this patient, specific antibodies fell immediately, followed by an increase within 1 week. The therapy group improved significantly in relation to the open controls in patients' subjective evaluation of symptoms (P < 0.028) and skin (P < 0.0001) and conjunctival (P < 0.001) sensitivity. Specific IgE increased in controls (P < 0.0001) but not in IT-treated patients during the "mite season"; that is, there was a significant difference in change during the observation period (P < 0.0001). There was also a difference in change of specific IgG between the groups during the first 4-5 months and the whole year (P < 0.0001), but not from 4-5 months to 12 months. In contrast to changes in antibody titers (IgG, P = 0.04), changes in conjunctival (P < 0.01) and especially skin sensitivity (P < 0.005) correlated well with subjective improvement. This implies that the skin prick test and the conjunctival test can be recommended for follow-up of IT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172356     DOI: 10.1111/j.1398-9995.1994.tb00808.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  5 in total

Review 1.  Immunotherapy for allergic diseases.

Authors:  J M Portnoy
Journal:  Clin Rev Allergy Immunol       Date:  2001-10       Impact factor: 8.667

Review 2.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).

Authors:  Eric Leith; Tom Bowen; Joe Butchey; David Fischer; Harold Kim; Bill Moote; Peter Small; Don Stark; Susan Waserman
Journal:  Allergy Asthma Clin Immunol       Date:  2006-06-15       Impact factor: 3.406

4.  Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients.

Authors:  Juliane Rieker-Schwienbacher; Marja J Nell; Zuzana Diamant; Ronald van Ree; Andreas Distler; Johan D Boot; Jörg Kleine-Tebbe
Journal:  Clin Transl Allergy       Date:  2013-05-08       Impact factor: 5.871

5.  Changes in skin reactivity and associated factors in patients sensitized to house dust mites after 1 year of allergen-specific immunotherapy.

Authors:  Jeong-Yeop Son; Mann-Hong Jung; Kwang-Wook Koh; Eun-Kee Park; Jeong-Hoon Heo; Gil-Soon Choi; Hee-Kyoo Kim
Journal:  Asia Pac Allergy       Date:  2017-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.